Pliant Therapeutics (PLRX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$22.4M

Net income growth (year over year)

+48.33%

Net margin

—

Return on equity

−50.29%

EPS (trailing twelve months)

−$1.50

Book value per share

$2.37

P/E (trailing twelve months)

—

Price to book

0.41

Debt to assets

22.62%

Payout ratio

—

Dividend yield

—

Company profile

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

• How do I buy stock in Pliant Therapeutics (PLRX)?

  PLRX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.